Overview

Par Pharmaceutical, Inc. is a subsidiary of Endo International plc, specializing in the development, manufacturing, and marketing of generic and specialty pharmaceutical products. The company focuses on delivering high-quality, cost-effective medications to improve patient health.

Therapeutic areas

API / Drug Master Files

Par Pharmaceutical, Inc. holds 2 active (5 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

  • SIROLIMUS (INTERMEDIATE)Active2020-07-31
  • PNEUMOCANDIN B0Active2018-04-27
  • SIROLIMUS (INTERMEDIATE)Inactive2017-12-27
  • MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN SPRING VALLEY, NEW YORK.Inactive1985-08-08
  • FACILITIES AND CONTROLSInactive1979-02-09

FDA compliance signals

17 FDA enforcement records linked to this company.

  • recall — Class II2020-09-02

    Failed Impurity /Degradation Specifications

  • recall — Class II2020-04-08

    Failed Impurities/Degradation Specification: Presence of unknown impurity observed.

  • recall — Class III2020-03-25

    Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg

  • recall — Class III2020-02-19

    Labeling: Incorrect or Missing Lot and/or Exp Date: Product incorrectly labeled with an expiration date of August 2022 rather than the correct expiration date of April 2022.

  • recall — Class I2019-05-15

    Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product

  • recall — Class III2018-09-19

    Failed impurities/degradation specifications: Finished product contain a known product impurity about current specification levels.

  • recall — Class II2016-12-07

    Lack of Assurance of Sterility; damage to the internal portion of the dropper tip portion of the container

  • recall — Class III2016-11-09

    Subpotent Drug; Ethinyl Estradiol

  • recall — Class III2016-11-09

    Subpotent Drug; Ethinyl Estradiol

  • recall — Class III2016-11-09

    Subpotent Drug; Ethinyl Estradiol

  • recall — Class III2016-11-09

    Subpotent Drug; Ethinyl Estradiol

  • recall — Class III2016-11-09

    Subpotent Drug; Ethinyl Estradiol

  • recall — Class III2016-06-22

    Failed Impurities/Degradation Specifications: Par Pharmaceutical is recalling Pramipexole Dihydrochloride Extended Release tablets because it contains a known product impurity above currently approved specification levels.

  • recall — Class III2015-11-25

    Failed Impurities/Degradation Specifications: Out of specification for impurities.

  • recall — Class III2015-11-25

    Failed Impurities/Degradation Specifications: Out of specification for impurities.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.